Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
Viking Therapeutics (NASDAQ: VKTX) announces it will release its Q1 2021 financial results after market close on April 28, 2021. A conference call to discuss these results and corporate updates will commence at 4:30 p.m. ET on the same day. Interested parties can participate via phone or listen online through the company's webcast. Viking is focused on developing therapies for metabolic and endocrine disorders, with key projects including VK2809 for NASH and VK0214 for X-ALD.
- Viking's clinical candidate VK2809 shows statistically significant improvements in lipid and liver metrics in trials.
- The company holds exclusive worldwide rights to five therapeutic programs, enhancing its development potential.
- None.
SAN DIEGO, April 21, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2021, after the market close on Wednesday, April 28, 2021.
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 28, 2021. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 5, 2021 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID #10153769. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2021-on-april-28-2021-301274177.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics report financial results for Q1 2021?
What time is the conference call for Viking's Q1 2021 results?
How can I listen to the Viking Therapeutics conference call?
What are the main clinical programs of Viking Therapeutics?
